F/m Emerald Life Sciences Innovation ETF

LFSC

Börsenwert 111 Mio. $

LFSC is a relatively new actively managed small-cap health care ETF with $49 million in assets under management and a 0.54% expense ratio after waivers. Although LFSC launched just five months ago, the team at Emerald Advisers is highly experienced and has managed a small-cap fund that's consistently outperformed its benchmark for 30+ years. With LFSC, Emerald leverages its proven ten-step bottom-up research process, which includes interviewing customers, competitors, and suppliers, and developing financial and valuation models.

LANCASTER, Pa.--(BUSINESS WIRE)--Emerald Advisers, in partnership with F/m Investments, today announces the launch of the F/m Emerald Life Sciences Innovation ETF (LFSC), now trading on the Nasdaq Stock Market under the ticker LFSC. This ETF offers investors exposure to the most innovative companies in the life sciences sector, focusing on biotech, healthcare, and medical device advancements. “We are excited to bring this ETF to market, offering investors access to some of the most cutting-edge.